| (Values in U.S. Thousands) | Mar, 2026 | Dec, 2025 | Sep, 2025 | Jun, 2025 | Mar, 2025 |
| Sales | 104,850 | 102,240 | 93,940 | 127,540 | 113,240 |
| Sales Growth | +2.55% | +8.84% | -26.34% | +12.63% | -2.52% |
| Net Income | -11,810 | -13,770 | -21,680 | 1,120 | -1,300 |
| Net Income Growth | +14.23% | +36.49% | -2,035.71% | +186.15% | -151.18% |
Accuray Inc (ARAY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Accuray Inc. designs, develops & sells radiosurgery and radiation therapy systems for treatment of tumors in the body. The company's product suite includes the CyberKnife Systems and the TomoTherapy Systems. It primarily generates revenues by selling the CyberKnife & TomoTherapy Systems and providing ongoing services and upgrades to customers following installation of the CyberKnife System. Product revenues include sales of linacs for other uses. It also offers optional hardware and software, technical enhancements and upgrades to the CyberKnife & TomoTherapy System. The CyberKnife Systems include: the CyberKnife G4, CyberKnife VSI System and the new CyberKnife M6 Series System. TomoTherapy Systems include the Hi-Art System, delivering CT-guided, helical intensity modulated radiation therapy; the TomoHD System and the Tomo H Series Systems.
Fiscal Year End Date: 06/30